

[a019]

Stereocontrolled preparation of substituted oxazolidin-2-one scaffold as the chiral building block for the synthesis of FTY720 analogues.

Kvetoslava Pomikalová, Miroslava Martinková and Jozef Gonda

Institute of Chemical Sciences, Department of Organic Chemistry, P. J. Šafárik University, Moyzesova 11, Košice, Slovak Republic


Abstract:

An efficient stereocontrolled synthesis of substituted oxazolidin-2-one synthon **11** as the key intermediate in the synthesis of FTY720 analogues starting from the highly functionalized furanose scaffold **2**¹ is reported.

Introduction:

In recent years, many immunosuppressants have been developed, some of which have been introduced in clinical organ transplantation. FTY720 **1**² is an immunosuppressive compound, which is efficacious in various models of autoimmune diseases and also transplantation.³ The development of FTY720 analogues (chiral and achiral) is desired in the investigation for the new immunomodulators.

Synthesis:



Reagents and conditions: (i) NaH, THF, 0 °C→RT, 30 min, 93%; (ii) TBAF, THF, 4Å molecular sieves, 0 °C→RT, 45 min, 85%; (iii) Ac₂O, pyridine, DMAP, RT, 40 min, 93%; (iv) TFA/H₂O (4:1), RT, 2 h, 79%; (v) NaIO₄, MeOH/H₂O (1:1), RT, 30 min, 96%; (vi) NaBH₄, MeOH, 0 °C, 2 h, 35%; (vii) TBDMSCl, DMAP, Et₃N, DMF, RT, 6 h, 62%; (viii) K₂CO₃, MeOH, 0 °C, 20 min, 48%; (ix) NaIO₄, MeOH/H₂O (1:1), RT, 3 h, 94%; (x) NaBH₄, MeOH, 0 °C, 45 min, 30%; (xi) TsCl, CH₂Cl₂, DMAP, Et₃N, RT, 6 h, 63%

Conclusion:

We have found an efficient route to interesting chiral building block **11**. We have also shown that this synthon **11** has suitable structure for further synthetic manipulations toward the FTY720 analogue **13**.

General experimental:

All commercially available reagents were used without purification, and solvents were dried by distillation from standard drying agents (under N₂). Thin layer chromatography (TLC) was used to monitor the progress and purity of compounds and performed on Merck Silica Gel 60 F₂₅₄ analytical plates. The compounds were visualized with a solution of *p*-anisaldehyde (**2**, **3**, **4**, **5**, **6**, **7**, **8**, **9**) or with a solution of phosphomolybdic acid (**10**, **11**), with subsequent heating. Column chromatography was done by using the flash chromatography technique, and was performed on silica gel 60 (0.040-0.063 mm, 230-400 mesh, Merck). Solvents for flash chromatography (hexane, dichloromethane, methanol and ethyl acetate) were distilled before using.

¹H and ¹³C NMR spectra were recorded on a Varian Mercury Plus 400 FT NMR spectrometer (400 MHz for ¹H and 100 MHz for ¹³C) using CD₃OD or CDCl₃ as the solvents and TMS as the internal standard. For ¹H chemical shifts are reported in parts per million relative to TMS (0 ppm) or CD₃OD (δ=4.84) and for ¹³C, they are reported relative to CDCl₃ (δ=77.0) or CD₃OD (δ=49.05). The melting points were determined on the Kofler block and are uncorrected. Optical rotations were measured with a P3002 Krüss polarimeter and reported as follows: [α]_D²⁵ (c in grams per 100 mL, solvent).

Acknowledgement:

The present work was supported by the Grant Agency (No.1/0100/09 and No.1/0281/08) of the Ministry of Education, Slovak Republic.

References:

- Martinková, M.; Gonda, J.; Raschmanová, J.; Vojtičková, M. *Tetrahedron* **2007**, *63*, 10603-10607.
- Adachi, K.; Kohara, T.; Nakao, N.; Arita, M.; Chiba, K.; Mishina, T.; Sasaki, S.; Fujita, T. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 853-856.
- Kiuchi, M.; Adachi, K.; Kohara, T.; Minoguchi, M.; Hanano, T.; Aoki, Y.; Mishina, T.; Arita, M.; Nakao, N.; Ohtsuki, M.; Hoshino, Y.; Teshima, K.; Chiba, K.; Sasaki, S.; Fujita, T. *J. Med. Chem.* **2000**, *43*, 2946-2961.
- Chiba, K.; Adachi, K. *Drugs Future* **1997**, *22*, 18-22.